Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that CEO David Stamler will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum on January 8, 2022, during the J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that CEO David Stamler will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum on January 8, 2022, during the J.P. Morgan Healthcare Conference. Dr. Stamler will join a panel titled 'New Approaches to Parkinson's and Movement Disorders,' provide a company update, and engage in investor meetings. The forum will address global bio-partnering advancements and scientific developments in neurodegenerative diseases, which includes key areas like neuropsychiatry and digital therapeutics.
Details
News Market Reaction – ATHE
The recorded move for ATHE in the trading session of this news was +4.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.
At the conference, Dr. Stamler will be featured on a panel entitled, "New Approaches to Parkinson's and Movement Disorders." He will also present a company update and participate in investor and business development meetings.
The program for the 6th Annual NIF is designed to cover the latest developments in global bio-partnering and investment, with additional panels covering scientific advances in key therapeutic areas of neurodegenerative diseases and CNS more broadly, which includes neuropsychiatry, ophthalmology, neurotech and digital therapeutics.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
View original content to download multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-to-participate-in-the-sachs-associates-6th-annual-neuroscience-innovation-forum-301712033.html
SOURCE Alterity Therapeutics Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.